tetano
Editor, Senior Moderator
Antib Ther
. 2020 Dec 28;3(4):285-299.
doi: 10.1093/abt/tbaa028. eCollection 2020 Dec.
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Yang Huang[SUP] 1 2 [/SUP], Hui Sun[SUP] 1 2 [/SUP], Hai Yu[SUP] 1 2 [/SUP], Shaowei Li[SUP] 1 2 [/SUP], Qingbing Zheng[SUP] 1 2 [/SUP], Ningshao Xia[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent human health crisis. Many SARS-CoV-2 neutralizing antibodies (NAbs) were developed with efficient therapeutic potential. NAbs-based therapeutics against SARS-CoV-2 are being expedited to preclinical and clinical studies with two antibody drugs, LY3819253 (LY-CoV555) and REGN-COV2 (REGN10933 and REGN10987), approved by the US Food and Drug Administration for emergency use authorization for treating COVID-19. In this review, we provide a systemic overview of SARS-CoV-2 specific or cross-reactive NAbs and discuss their structures, functions and neutralization mechanisms. We provide insight into how these NAbs specific recognize the spike protein of SARS-CoV-2 or cross-react to other CoVs. We also summarize the challenges of NAbs therapeutics such as antibody-dependent enhancement and viral escape mutations. Such evidence is urgently needed to the development of antibody therapeutic interventions that are likely required to reduce the global burden of COVID-19.
Keywords: COVID-19; SARS-CoV-2; hACE2; neutralizing antibodies; spike protein
. 2020 Dec 28;3(4):285-299.
doi: 10.1093/abt/tbaa028. eCollection 2020 Dec.
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Yang Huang[SUP] 1 2 [/SUP], Hui Sun[SUP] 1 2 [/SUP], Hai Yu[SUP] 1 2 [/SUP], Shaowei Li[SUP] 1 2 [/SUP], Qingbing Zheng[SUP] 1 2 [/SUP], Ningshao Xia[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 33912797
- PMCID: PMC7799234
- DOI: 10.1093/abt/tbaa028
Abstract
The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent human health crisis. Many SARS-CoV-2 neutralizing antibodies (NAbs) were developed with efficient therapeutic potential. NAbs-based therapeutics against SARS-CoV-2 are being expedited to preclinical and clinical studies with two antibody drugs, LY3819253 (LY-CoV555) and REGN-COV2 (REGN10933 and REGN10987), approved by the US Food and Drug Administration for emergency use authorization for treating COVID-19. In this review, we provide a systemic overview of SARS-CoV-2 specific or cross-reactive NAbs and discuss their structures, functions and neutralization mechanisms. We provide insight into how these NAbs specific recognize the spike protein of SARS-CoV-2 or cross-react to other CoVs. We also summarize the challenges of NAbs therapeutics such as antibody-dependent enhancement and viral escape mutations. Such evidence is urgently needed to the development of antibody therapeutic interventions that are likely required to reduce the global burden of COVID-19.
Keywords: COVID-19; SARS-CoV-2; hACE2; neutralizing antibodies; spike protein